Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Inhibition of lipid synthase activity: AOD 9604 reduces the activities of fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC), and decreases de novo synthesis of fatty acids
It can balance the immune response and regenerate tissues in IBD patients
Better Med Spa members receive additional savings on peptide protocols
Not for human use or diagnostic/therapeutic applications
As of July 2026, that application remains under review, and CagriSema is not approved in the United States or the European Union
Any discussion of BPC-157 is education-only and focused on oral supplement options
